Evidence map›Paper›PMID 39927773›Full record

ArticleJournal of virology2025

Generation of RNA aptamers against chikungunya virus E2 envelope protein.

Kaku Goto, Ryo Amano, Akiko Ichinose, Akiya Michishita, Michiaki Hamada, Yoshikazu Nakamura, Masaki Takahashi

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kaku GotoProject Division of RNA Medical Science, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-3717-1132
Ryo AmanoProject Division of RNA Medical Science, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Akiko IchinoseGraduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan.
Akiya MichishitaGraduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan.
Michiaki HamadaGraduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan.
Yoshikazu NakamuraProject Division of RNA Medical Science, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Masaki TakahashiProject Division of RNA Medical Science, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-1190-2213

Funding

Grant-in-aid for Challenging Research (Exploratory) 17K20087JST CREST JPMJCR21F1
6 · The paper itself

Abstract

Nucleic acid aptamers are a promising drug modality, whereas the generation of virus-neutralizing aptamers has remained difficult due to the lack of a robust system for targeting the viral particles of interest. Here, we took advantage of our latest platform technology of Systematic Evolution of Ligands by EXponential enrichment (SELEX) with virus-like particles (VLPs) and targeted chikungunya virus (CHIKV) as a model, the pathogenic reemerging virus with an unmet need for control. The identified aptamer against CHIKV-VLPs, Apt#1, and its truncated derivatives showed neutralizing activity with nanomolar IC50 values in a cell-based assay system using a pseudoviral particle of CHIKV (CHIKVpp). An antiviral-based chemical genetics approach revealed significant competition of Apt#1 with suramin, a reported interactant with domain A of the E2 envelope protein (E2DA), in both CHIKVpp and surface plasmon resonance (SPR) analyses, predicting E2DA to be the Apt#1 interface. In addition, Apt#1 interfered with the attachment of CHIKVpp, collectively suggesting its property as an attachment inhibitor via E2DA of CHIKV. Thus, the generation of the VLP-targeted aptamers proved to contribute to anti-CHIKV strategies and confirmed the utility of the platform as a novel and viable option for the development of neutralizing agents against viral particles of interest.IMPORTANCEOur latest SELEX technology using VLPs has generated aptamers that bind the native conformation of the incorporated envelope protein and achieve the virus binding and neutralizing effects. Indeed, the aptamer-probed target E2DA is a representative neutralization site on the surface of the viral particle, validating the utility of the VLP-driven procedure. Simultaneously, the enhanced antiviral effects of the aptamer in combination with approved drugs using the CHIKVpp assay with human cells indicated potential therapeutic strategies that are expected to help address unmet needs in CHIKV control. The robust affinity of the aptamer to viral particles demonstrated by SPR analysis can also lead to conjugates with antivirals as guiding molecules and aptasensors for diagnostic tools. Overall, our VLP-based method provided anti-CHIKV as well as a versatile platform applicable to other emerging and reemerging viruses, in preparation for outbreaks with the need for rapid development of antiviral strategies as next-generation theranostics.

Indexed as

Antiviral AgentsAptamers, NucleotideChikungunya virusViral Envelope ProteinsAnimalsCell LineChikungunya FeverHumansSELEX Aptamer TechniqueSuraminSurface Plasmon ResonanceVero CellsVirus AttachmentAntiviral AgentsAptamers, NucleotideSuraminViral Envelope ProteinsaptamerCHIKVneutralization

Identifiers

PMID39927773
PMCPMC11915788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.